BioXcel Therapeutics, Inc.
NASDAQ: BTAI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vimal D. Mehta
- Employees
- 37
- Headquarters
- New Haven, United States
- IPO year
- 2018
- Market cap
- $40.4M
- Website
- https://www.bioxceltherapeutics.com
Loading BTAI…
Loading profile data…Frequently asked questions about BTAI
What does BioXcel Therapeutics, Inc. (BTAI) do?
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power...
Where does BTAI trade?
BioXcel Therapeutics, Inc. (BTAI) trades on the NASDAQ Capital Market.
What sector is BTAI in?
BioXcel Therapeutics, Inc. (BTAI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioXcel Therapeutics, Inc.?
Vimal D. Mehta is the chief executive officer of BioXcel Therapeutics, Inc. (BTAI).
Where is BioXcel Therapeutics, Inc. headquartered?
BioXcel Therapeutics, Inc. is headquartered in United States.
Does BTAI pay a dividend?
BioXcel Therapeutics, Inc. (BTAI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BTAI go public?
BioXcel Therapeutics, Inc. (BTAI) completed its initial public offering in 2018.